financetom
Business
financetom
/
Business
/
Ryanair trims traffic forecast again on Boeing delays
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ryanair trims traffic forecast again on Boeing delays
Jan 26, 2025 10:32 PM

DUBLIN, Jan 27 (Reuters) - Ryanair reported

after-tax profit for the three months to the end of December

ahead of analyst forecasts on Monday, but Europe's largest

low-cost carrier again trimmed its forecast for passenger

numbers on Boeing ( BA ) delivery delays.

After tax-profit for the third quarter of Ryanair's

financial year was 149 million euros ($156 million), well ahead

of the 60 million euro profit forecast in a company poll of

analysts.

That was mainly due to a better-than-expected 1% increase in

average fares in the quarter, compared to a fall of 7% during

the previous quarter, Chief Financial Officer Neil Sorahan said.

($1 = 0.9564 euros)

(Writing by Conor Humphries; Editing by Christian Schmollinger)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
VinFast Hits Roadblock: Fails To Meet Q2 Earnings And Sales Expectations, Cautions On Challenging Macro EV Outlook
VinFast Hits Roadblock: Fails To Meet Q2 Earnings And Sales Expectations, Cautions On Challenging Macro EV Outlook
Sep 20, 2024
VinFast Auto Ltd. ( VFS ) shares are trading lower in the morning session on Friday. The company reported a second-quarter loss per share of 33 cents, missing the street view of a 21-cent loss. Quarterly sales of $357.4 million missed the analyst consensus of $460.09 million. “We have acknowledged some headwinds and uncertainties adversely challenging EV outlook at this...
US FDA approves Zevra's genetic disorder treatment
US FDA approves Zevra's genetic disorder treatment
Sep 20, 2024
Sept 20 (Reuters) - The U.S. Food and Drug Administration approved Zevra Therapeutics' ( ZVRA ) drug for a rare and fatal genetic disorder, the first treatment to get a nod for the condition, the health regulator said on Friday. (Reporting by Sriparna Roy and Kashish Tandon in Bengaluru; Editing by Devika Syamnath) ...
Alpha Tau Medical Gets FDA Approval to Start Alpha DaRT Cancer Therapy Study
Alpha Tau Medical Gets FDA Approval to Start Alpha DaRT Cancer Therapy Study
Sep 20, 2024
10:14 AM EDT, 09/20/2024 (MT Newswires) -- Alpha Tau Medical ( DRTS ) said Friday that the US Food and Drug Administration approved its investigational device exemption application to start a multi-center study on Alpha DaRT as a treatment for recurrent cutaneous squamous cell carcinoma in immunocompromised patients. The company said the approved study design allows for the enrollment of...
TransDigm to Pay $75 Per Share Special Dividend; Unit Issues $3 Billion of Debt
TransDigm to Pay $75 Per Share Special Dividend; Unit Issues $3 Billion of Debt
Sep 20, 2024
10:11 AM EDT, 09/20/2024 (MT Newswires) -- TransDigm Group ( TDG ) said Friday its board approved a special cash dividend of $75 on each outstanding share and dividend equivalent payments on eligible vested options provided under its stock option plans. The supplier of aircraft components said Oct. 4 is the record date for the dividend, which will be paid...
Copyright 2023-2026 - www.financetom.com All Rights Reserved